As the demand for donors for bone marrow ranplantation increases, the use of HLA-matched, gently unrelated donors represents a promising strategy. It is well documented that the clinical outcome of bone marrow transplantation is directly dependent on optimal matching for HLA class I and clss H specificities. Molecular studies have revealed the existence of a much larger number of HLA class II alleles than was antipated, many of which cannot be recognized by routine serolgical typing. Bone marrow transplantation (BMT) represents a major therapeutic option in the treatment of patients with leukemia and bone marrow failure syndromes (1). Unfortunately, 60-70% ofthese patients lack an HLA-matched related donor (2). Clinical studies have demonstrated the feasibility of using partially mismatched family members or partially or fully matched unrelated volunteers as marrow donors (3-8). Although the availability of unrelated donors is potentially very large, one important limitation is the accuracy of HLA matching of such donors, in particular for the large number of allelic differences that remain undetected by standard serological typing (9). Indeed, clinical experience with patients receiving a marrow graft from unrelated donors or haplo-identical family donors has shown that graft failure and acute graft-versus-host disease increase as the extent of HLA mismatch increases (5-8).
differences influence the primary mixed lymphocyte culture. We show that HLA oligotyping, performed on 50 pairs of HLA class I and II serologically matched individuals, can indeed reveal phenotypically relevant allelic differences at eitherDR8 orDQB loci in 56% of these pairs and can therefore improve ILA class H typing and the choice of bone marrow donors quite signntly. Oigotyping for DRB/DQB/DPB polymorphism also allows prediction of a positive mixed lymphocyte culture, as established in 31 donor/recipient combinations, and even detectin of polymorphic differences that were not revealed by this test. This approach is well suited for accurate HLA typing of large pools of bone marrow donors and was successfully applied to select ful mated donors for bone marrow transplantation.
Bone marrow transplantation (BMT) represents a major therapeutic option in the treatment of patients with leukemia and bone marrow failure syndromes (1) . Unfortunately, 60-70% ofthese patients lack an HLA-matched related donor (2) . Clinical studies have demonstrated the feasibility of using partially mismatched family members or partially or fully matched unrelated volunteers as marrow donors (3) (4) (5) (6) (7) (8) . Although the availability of unrelated donors is potentially very large, one important limitation is the accuracy of HLA matching of such donors, in particular for the large number of allelic differences that remain undetected by standard serological typing (9) . Indeed, clinical experience with patients receiving a marrow graft from unrelated donors or haplo-identical family donors has shown that graft failure and acute graft-versus-host disease increase as the extent of HLA mismatch increases (5) (6) (7) (8) .
The cloning and sequencing of HLA class II genes have revealed an unsuspected degree of diversity of HLA class II molecules. This approach has established in particular that polymorphism at several class II loci (i.e., DRBJ, DRB3, DQBJ, DQAJ, and DPBI) is much greater than was identified from current HLA class II typing by serology (9) . A large number of allelic subtypes thus represent "hidden alleles," undetectable by conventional methods. Fortunately, the availability of cloned HLA class II genes makes it possible to analyze the polymorphism directly at the level of DNA (genotyping). We first proposed such an analysis based on restriction fragment length polymorphism (RFLP) (10) . More recently we have presented another approach to genotyping, based on the direct recognition of allelic sequences by hybridization with locus-and allelespecific synthetic oligonucleotides ("HLA oligotyping") (11) and have shown that class II micropolymorphism can be accurately analyzed down to single amino acid differences. This HLA oligotyping procedure can now be simplified by the use of DNA previously amplified by the polymerase chain reaction (PCR) (12, 13) .
Based on the availability of DNA sequence information for all known alleles of DRB, DQB, and DPB loci, we have developed conditions allowing the identification of all DRBI, DRB3, DRBS, DQBJ, and DPBJ alleles in heterozygous individuals with an appropriate choice of informative sequence-specific oligonucleotides (14) (15) (16) (17) (18) . Our oligotyping system involves two successive steps. In step 1 (HLA-DR generic typing), a battery of 14 sequence-specific probes is used to identify all major DR specificities (DR] to DRw14) (17, 18) . For the second step, oligonucleotide probes are chosen appropriately in order to allow the identification of almost all 45 DRBI, 4 DRB3, 4 DRBS, 15 DQBJ, and 20 DPBJ alleles (14) (15) (16) (17) (18) (19) . This two-step procedure makes an optimal use of the sequence information for an unambiguous characterization of micropolymorphic HLA differences.
In this paper, we have tested the potential ofoligotyping for a better matching of HLA-identical unrelated donors for BMT. HLA-DR, -DQ, and -DP oligotyping analysis of pairs of class I and II serologically identical individuals showed that oligotyping can detect HLA class II sequence differences that are not seen by serology, RFLP, or even the mixed lymphocyte culture (MLC).
MATERIAL AND METHODS
The HLA phenotypes were determined on peripheral blood lymphocytes by microlymphocytotoxicity using wellstandardized alloantisera.
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The MLC assay, based on the incorporation of [3H]thymidine performed in triplicate, has been described (20) . In each experiment, three unrelated individuals were used as positive controls. Their HLA-DR, -DQ antigens differed between themselves and between the pair investigated. The intensity ofcell proliferation was calculated as the percentage of stabilized relative response (% SRR) (21) . Between HLA unrelated pheno-identical pairs a SRR of <20% was considered as negative MLC.
DNA was extracted from peripheral blood lymphocytes or granulocyte pellets from Ficoll gradients obtained from 10-20 ml of blood as described (15, 16) . One-microgram DNA samples were amplified (12, 13) in a 50-,ul reaction using Taq polymerase (1.25 units per reaction; Anglian Biotec, Colchester, U.K.) as described (15, 16) . The sequences ofthe DRB primers (15) , DQB primers (i6), and DPB primers (22) have been described elsewhere. The DRB, DQB, and DPB amplified gene segments are 292 base pairs (bp), 208 bp, and 294 bp, respectively. Aliquots of 1/20th of the PCR reaction were loaded on a GeneScreenPlus or Biotrace filter using a Schleicher & Schull slot blot Minifold II apparatus and denatured in situ in 0.4 M NaOH.
The blots were prehybridized, hybridized, washed, and exposed for autoradiography as described in detail (15, 23) . Following PCR amplification, DNA from each sample was first analyzed for HLA-DR with the set of 14 informative oligonucleotides used in step 1 of the oligotyping procedure that identify DR] to DRwJ4 (14, 15, 17, 18) . For step 2 of the oligotyping procedure, oligonucleotides known to split these DR specificities and to detect the different possible DQB alleles generally associated were used (16, 18) . DQBJ is much more polymorphic (19) and therefore more informative than DQAI. A representative selection of the hybridization results is shown in Fig. 1 . Taking into consideration all serologically HLA identical pairs formed with the individuals presented in Table 1 (including additional matched donors), we have compared serology and JRB/DQB oligotyping in 50 unrelated pairs of HLA class II serologically matched individuals. In 28 cases (56%) oligotyping revealed allelic differences at either DR and/or DQ loci.
Correlation Between HLA Class II Oligotyping and MLC. Thirty-one serologically identical pairs were also analyzed by the primary MLC and by DPB1 oligotyping (Table 1 ). In each ofthese 31 pairs a comparison can therefore be made between the resolution obtained by serological typing, MLC, and oligotyping. The data are summarized in Table 1 . Two relatively frequent haplotypes were found to be well conserved at the level of oligonucleotide analysis-namely, AJ-B8-DR3-DRw52a-DQw2 (23) (present in 26% of the pairs) and A29-B44-DR7-DQw2 (16% of the pairs).
In 21 of the 31 pairs the MLC was negative (in at least two independent experiments) or, in two cases, uninterpretable (Table 1 ). In 14 of these 21 pairs, oligotyping analysis did not reveal any difference at DRBI, DRB3, DRBS, or DQBJ loci (see, for example, pair VI, Fig. 1A ). In the remaining 7 pairs, however, allelic differences were detected by oligotyping either at locus DRBI (pair IV, Fig. 1B; pair VIII, Fig. 1C ; pair Table 1 ). In pair II, the DQw3 subtypes (DQw7 versus DQw8) were also confirmed by serology. Interestingly, therefore, DR or DQ allelic differences that are not revealed at the level of MLC can be identified by genotyping. Pairs IV, VIII, XIV, XV, XIX, and XXII concerned leukemic patients and their potential donors.
With pairs ofgenotypically identical siblings, the MLC test is generally negative. In the case of genetically unrelated donors, however, serological identity might still imply class II allelic differences and result in a positive MLC (24, 25) . It is generally admitted that T-cell proliferation in primary MLC is induced by incompatibilities at HLA-DR and -DQ. Although HLA-DP seems to be of minor importance, DPmediated positive MLC can nevertheless be expected in some cases of HLA identical unrelated donors (25) (26) (27) oligotyping is now systematically performed in our laboratory for the selection of optimally matched donors for BMT. Fig. 2 illustrates the cases of two leukemic patients for whom several potential unrelated donors had been selected on the basis of identity for HLA class I and class II by serology. In the case shown in Fig. 2A , the patient and the five potential donors were analyzed systematically for DR and DQ micropolymorphism. Three HLA identical donors unequivocally exhibit allelic differences and only donor 1 and donor 2 are genotypically fully matched with the patient for HLA-DR and -DQ. In this case the results of the MLC correlated well with the oligotyping analysis and had therefore been predicted on the basis of oligotyping. Fig. 2B shows the case of Oligotyping analysis for HLA-DR and -DQ micropolymorphism of a CML patient (DR2/4; DRB1*1501/0404-DRB5*0101-DQB1*0602/0302) and his five serologically class I and class II identical unrelated potential donors. Oligonucleotide probes allowing detection of splits ofDR2, DR4, DQwI, and DQw3 were used as described in legend to Fig. 1 and in the text. Arrows point to the only two donors who are fully matched with the patient for DRBI, DRBS, and DQBI. The remaining three donors either differed for the DR4 subtype (d3, d4) or DR2 subtype (d5) and the DQw3 subtype (d3, d4) or DQwJ subtype (d5). The MLC was negative with both dl and d2. (B) Oligotyping analysis for HLA-DR and -DQ micropolymorphism of an acute lymphoblastic leukemia patient (DRJ/w13; DRB1*0101/1302-DRB3*0301-DQB1*0501/0604) and his three serologically class I and class II potential unrelated donors. The arrow points to the single donor who is fully matched with the patient (for DRBI, DRB3, and DQBJ), although the MLC was negative not only with that dl but also with d3, who differs with the patient at all three loci. a second patient and three potential donors. Oligotyping indicates that only donor 1 is HLA-DR and -DQ identical with the patient. Donors 2 and 3 both differ from the patient at locus DRBJ (1302-1301 mismatch), locus DRB3 (0201-0101 mismatch), and locus DQBI (0604-0603 mismatch). Interestingly, genotypic differences between patient and donor 3, which were easily identified by oligotyping, could not be detected by MLC.
DISCUSSION
Functional allelic polymorphism of major histocompatibility complex class II genes plays a key role in the regulation ofthe immune response and in transplantation immunology. The contribution of the allelic diversity of class II genes to immune recognition and alloreactivity can now be analyzed directly at the DNA level by oligotyping with locus-and allele-specific oligonucleotide probes (11, 14, 15-18, 23, 28) . HLA class II matching appears to be a particularly relevant issue in BMT (8, 29) and will probably become more important as transplantation programs with unrelated donors are developed on a large scale. This paper provides one application of HLA oligotyping to bone marrow donor selection with a correlation between direct DRB/DQB/DPB genotyping and cellular reactivity.
In this report we demonstrate that oligotyping on PCRamplified DNA is particularly useful in the matching of cells from leukemic patients, which are notoriously difficult to type by serology. Indeed oligotyping has recently been applied to HLA typing of a patient with HLA-deficient combined immunodeficiency and his potential bone marrow donor (30) . In addition, we show here that oligotyping allows a precise identification ofHLA-DR, -DQ, and -DP micropolymorphism for any class I and class II serologically identical unrelated donor/recipient pair (Table 1) (14, 31) . Altogether, out of 50 pairs of HLA class I and II serologically matched individuals analyzed in the course of this study, DR and/or DQ mismatches were detected by oligotyping in 28 cases (56%).
In the case of seven pairs [II, IV, VIII, XIV, XV, XIX (Fig.  2B, d3) , and XXII ( Fig. 2A, d3) (18) , has been successfully applied to the case of two leukemic patients. As shown in Fig. 2 (37) , clinically important parameters in the choice of a donor for transplantation may not only be the number of mismatches but rather the nature of a particular mismatch, since the functional consequences of different kinds of HLA allelic differences will probably differ. Eventually such information on a hierarchy of clinical permissiveness among different HLA class II mismatches will be of great practical value in the selection ofunrelated donors. This is especially true since the increased accuracy of HLA typing will make it more and more difficult to identify genotypically fully matched donors, particularly in the case of rare haplotypes (2) .
